Shanghai Baiyi Healthcare Technology Showcases Innovative Medical Technology at International Forum, Driving Standardization in the Diagnosis and Treatment of Thyroid Eye Disease
London, United Kingdom–(Newsfile Corp. – September 29, 2025) – The 2025 Global Forum of the European Group on Graves’ Orbitopathy (EUGOGO) grandly opened recently in London, the United Kingdom. As a top-tier academic event in the field of diagnosis and treatment of thyroid eye disease, this forum has brought together leading experts and scholars worldwide to jointly discuss diagnostic and therapeutic standards as well as technological innovations. The “Automatic Ocular Signometer BY-O1A” developed by Shanghai Baiyi Healthcare Technology Co., Ltd. (Baiyi Healthcare), an innovative Chinese medical device enterprise, is the only medical device product has been invited from China.
EUGOGO Global TED Forum 2025 – Shanghai Baiyi Healthcare Technology Showcases Innovative Medical Technology at International Forum
To view an enhanced version of this graphic, please visit:
As an international authoritative organization promoting clinical research and multidisciplinary diagnosis and treatment of Graves’ orbitopathy (also known as thyroid eye disease), EUGOGO has consistently conducted high-quality clinical research through cross-border collaboration, formulated evidence-based guidelines, and led the development of global diagnosis and treatment standards since its establishment in 1999.
This Forum Focuses on Standardization and Precision in the Diagnosis and Treatment of Thyroid-Related Eye Diseases. Experts attending the forum generally pointed out that the current diagnosis and treatment still face common challenges such as insufficient quantitative tools and strong subjectivity in evaluation. There is an urgent need for a standardized measurement technology and evaluation method that is “objectively repeatable, accurate and traceable”.
The “Automatic Ocular signometer (BY-O1A)” provided by Baiyi Healthcare has precisely provided a “Chinese solution” to this international challenge. It is reported that this device has obtained the registration certificate for innovative Class II medical devices from China National Medical Products Administration (NMPA). It can automatically measure core indicators such as exophthalmos (eyeball protrusion) and palpebral fissure width with sub-millimeter precision, effectively solving the key technical problems in standardizing clinical evaluation. Furthermore, it fills the international gap in specialized diagnostic equipment for this field and provides an innovative solution for the precise diagnosis and treatment of thyroid eye disease.
link
